Skip to main
HROW
HROW logo

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow Inc. is strategically positioned to capitalize on the growing market for biosimilars, which has seen a penetration rate exceeding 40% in key therapeutic categories since 2015, aligning with healthcare cost reduction efforts. The company is projected to experience significant revenue growth, with expectations for quarterly revenue run rates to exceed $250 million by the fourth quarter of 2027, representing an increase of nearly four times compared to actual figures from the second quarter of 2025. Continued prescription growth momentum, as evidenced by recent data from IQVIA and Symphony Health, further supports the positive outlook for Harrow's product sales moving forward.

Bears say

Harrow Inc faces significant risks related to its product development pipeline, particularly concerning the ability of its spinouts to generate favorable clinical data and achieve regulatory approval, which could adversely impact the company's overall valuation. Furthermore, the potential for slow adoption rates of Harrow's existing and new assets poses an additional threat to the firm's financial performance, as any delays in market acceptance could lead to diminished revenue projections. Lastly, the possibility of unfavorable regulatory changes could further disrupt Harrow's operations and negatively influence its financial stability.

HROW has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 6 analysts, HROW has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.